The OBR Blog

July 05, 2011 - 07:07 am Posted in Featured comments0 Comments

Last week we published Post-ASCO QuickPoll data in melanoma, and now this week we’ll explore another important tumor type – GU cancers. QuickPolls are a first glimpse into physicians’ reactions to new data presented at ASCO ’11. OBR and MDoutlook are pleased to share results from MDoutlook’s 4th annual post-ASCO survey fielded among its global network of 52,000 cancer physicians.


Quick Poll Methodology and Respondents’ Geographic Distribution

  • 2011 American Society of Clinical Oncology (ASCO) Annual Meeting was held in Chicago, IL. June 3-7, 2011
  • GU Malignancies Quick Poll was launched by email in the morning of Thursday, June 9, 2011
  • Sent to global distribution of Medical Oncologists and clinicians (including urologists) with a clinical interest in genitourinary malignancies (prostate and/or renal cell)
  • Data taken on June 15th with 102 complete responses
  • ~1/2 of responses from USA
  • Responses received from 22 different countries in total
  • No financial incentives provided for participation

Survey Results:

1) Axitinib is Expected to Have a High Impact on the Clinical Practice for Metastatic Renal Cell Carcinoma


  • Majority of respondents rated Abstract#4503 (Axitinib in mRCC) as having a High or Very High clinical importance
  • Only ~4% of respondents viewed this information as poor
  • Practitioners outside of the US had a slightly more positive outlook of this information

2) Axitinib Will be Widely Used in Metastatic Renal Cell Carcinoma Following Treatment with Sunitinib


  • Axitinib is expected to become the preferred 2nd line treatment for metastatic RCC (mRCC) following failure/progression on sunitinib
  • mTOR inhibitors are the next most common choice
  • Most clinicians will use a variety of these agents (data not shown)
  • Less than 1/3 will use a single option in the majority of their patients

3) Increasing Usage of Intermittent Androgen Suppression Upon Rising PSA Levels


  • Currently, slightly more use of continuous androgen suppression upon rising PSA  levels
  • Vast majority of clinicians are using both approaches in their practice (data not shown)
  • Clinicians expect to increase their usage of intermittent androgen suppression for these patients
  • Decision of intermittent vs. continuous suppression is made on an individual patient basis (i.e. most will still use both approaches in their practices)
  • Mostly similar results across geographic regions; Slightly higher adoption of intermittent approach in the US

4) Abiraterone and Cabazitaxel are Seen as the Most Valuable New Therapeutics for Prostate Cancer


  • Abiraterone acetate is the highest rated new therapeutic for prostate cancer
  • Below average value in prostate cancer is seen for only sunitinib
  • Overall, the US respondents are more enthusiastic about these agents than those outside of the US

Overall Conclusions:

  • The new TKI inhibitor axitinib is likely to make a positive impact on the treatment of metastatic renal cell carcinoma –Expected to be the most common 2nd line therapy following sunitinib
  • Clinicians use a wide variety of agents for the post-sunitinib treatment of mRCC
  • While most have their own clear favorite approach, almost all use a variety of agents
  • For patients with prostate cancer, the use of intermittent androgen suppression will increase at the expense of continuous suppression
  • Abiraterone and cabazitaxel are seen as the best new therapeutics for prostate cancer Includes those recently approved and under clinical development

Final Thoughts:

Quick polls are a fast way of measuring expected acceptance of clinical data post major medical meetings, and perhaps can be used to make some assumptions about adoption amongst providers.  In today’s information hungry environment, the speed at which these polls can be conducted and analyzed can be advantageous for market planning and “pressure testing” acceptance of data amongst key stakeholders.

article register

Recent Posts

Recent Comments